Eris Lifesciences Limited
Eris Lifesciences Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.
Peers in Healthcare
Top 8 by market cap| Company | LTP | 30D | Market Cap | P/E | P/B | ROE % | Div Yld % |
|---|---|---|---|---|---|---|---|
| Eris Lifesciences Limited(this stock) | ₹1,399 | ₹18755.08 Cr | 29.9 | 6.0 | 18.1% | 1.07% | |
| Divi's Laboratories LimitedDIVISLAB | ₹6,667 | ₹179363.84 Cr | 72.1 | 11.6 | 16.2% | 0.44% | |
| Torrent Pharmaceuticals LimitedTORNTPHARM | ₹4,410.8 | ₹154757.56 Cr | 71.8 | 18.3 | 17.0% | 0.78% | |
| Apollo Hospitals Enterprise LimitedAPOLLOHOSP | ₹8,176.5 | ₹120994.79 Cr | 62.5 | 12.8 | 21.5% | 0.24% | |
| Zydus Lifesciences LimitedZYDUSLIFE | ₹1,077.7 | ₹107963.87 Cr | 21.4 | 4.3 | 18.3% | 0.10% | |
| Mankind Pharma LimitedMANKIND | ₹2,375.6 | ₹101472.43 Cr | 53.0 | 6.6 | 12.4% | 0.08% | |
| Max Healthcare Institute LimitedMAXHEALTH | ₹965.1 | ₹97382.77 Cr | 67.9 | 9.7 | 14.3% | 0.15% | |
| Aurobindo Pharma LimitedAUROPHARMA | ₹1,426.4 | ₹83694.47 Cr | 24.1 | 2.2 | 9.9% | 0.27% | |
| Fortis Healthcare LimitedFORTIS | ₹928.45 | ₹73257.36 Cr | 70.2 | 7.8 | 11.0% | 0.10% |
News & FilingsGoogle News + BSE
Eris Lifesciences Q4 profit jumps three-fold to ₹281.6 cr; shares surge 11%
Business Standard· 20 MayInvestors Appear Satisfied With Eris Lifesciences Limited's (NSE:ERIS) Prospects
simplywall.st· 15 JanEris Lifesciences shares gain 4% on partnering with Natco Pharma to launch semaglutide in India
Upstox· 24 FebStocks to Watch Today: Diamond Power, Surya Roshni, Eris Lifesciences, Ceigall India, Niraj Cement,...
Moneycontrol.com· 25 NovEris Lifesciences Fined ₹65,000 Each by BSE and NSE for Board Composition Non-Compliance
scanx.trade· 28 FebNatco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in India
The Economic Times· 24 Feb
News via Google News · Not verified by IPOpulse · Not investment advice
Community discussion(0)
Sign in to join the discussion.
Sign inNo comments yet — be the first to share your view.